The Morning Brief Semaglutide Goes Generic: Big Pharma’s Moat Breaks
24 snips
Mar 19, 2026 Sheetal Sapale, VP at Pharmarack who tracks pharma market and pricing in India, and Dr. Rajiv Kovil, diabetologist and weight‑management expert, unpack semaglutide’s patent expiry. They discuss the incoming generic surge and steep price drops. They debate cold‑chain and manufacturing hurdles, patient adherence and education, shifting treatment pathways, and who might scale up or falter in the shakeout.
AI Snips
Chapters
Transcript
Episode notes
Run Patient Support Or Expect High Dropouts
- Invest in patient education and sustained patient-support programs to reduce the high early dropout rates.
- Dr. Saurabh Jain warns over 50% of patients stop GLP-1 therapy within a year without effective education and NDRS support.
Generics Could Triple Market Size By 2030
- Patent expiry will likely cut prices to one-third and triple volumes, expanding India’s anti-obesity market to an estimated ₹6,000–8,000 crore by 2030.
- Sheetal Sapale projects monthly cost falling from ~₹10,000 to ₹3,000–4,000 and volumes rising 2–3x.
Execution Matters More Than Just Low Price
- Manufacturing and cold-chain execution, not just price, will decide winners; many entrants may fail.
- Saurabh Agarwal stresses semaglutide is a complex peptide requiring device integration and reliable cold distribution in India.